Skip to main content

THE SAFETY PHARMACOLOGY OF ARTEMISININS WHEN USED TO REVERSE PATHOPHYSIOLOGY OF MALARIA IN PREGNANCY

Objective

Artemisinin based antimalarial drug combinations are recommended for the treatment of P.falciparum malaria infections throughout all malarial endemic areas of the world and in all populations, including women of child bearing age. The studies planned in this collaborative project are central to assessing the potential hazard posed by these drugs to the developing human foetus and thereby making evidence based recommendations on the risk:benefit of these drugs. Although clinical experience to date indicates the artemisinins to be safe, the area of reproductive toxicology demands special consideration. Data from the Chinese literature and our own studies confirm that the artemisinins are embryotoxic and potentially teratogenic in animal species at drug doses within the human therapeutic range. Based on over ten years of investigating the pharmacology of these drugs we have developed a hypothesis which can explain these teratogenic effects. Our hypothesis is based on the generation of reactive oxygen species (ROS) from cleavage of the artemisinin peroxide bridge and consequent embryofoetal damage to key biological macromolecules. Our hypothesis draws on parallels with the metabolic activation and teratogenic effects of the other established teratogens such as phenytoin

Field of science

  • /medical and health sciences/health sciences/infectious disease/malaria
  • /humanities/languages and literature/literature - general
  • /medical and health sciences/basic medicine/pharmacology and pharmacy
  • /medical and health sciences/basic medicine/toxicology

Call for proposal

FP7-HEALTH-2007-A
See other projects for this call

Funding Scheme

CP-FP - Small or medium-scale focused research project

Coordinator

LIVERPOOL SCHOOL OF TROPICAL MEDICINE
Address
Pembroke Place
L35QA Liverpool
United Kingdom
Activity type
Higher or Secondary Education Establishments
EU contribution
€ 733 480
Administrative Contact
Stephen Ward (Prof.)

Participants (5)

THE UNIVERSITY OF LIVERPOOL
United Kingdom
EU contribution
€ 384 880
Address
Brownlow Hill 765 Foundation Building
L69 7ZX Liverpool
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Veronica Cannings (Ms.)
UNIVERSIDADE DO ALGARVE
Portugal
EU contribution
€ 194 680
Address
Campus De Penha
8005 139 Faro
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Maria De Lurdes Cristiano (Prof.)
UNIVERSITEIT LEIDEN
Netherlands
EU contribution
€ 402 880
Address
Rapenburg 70
2311 EZ Leiden
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Ton Bouw Er (Mr.)
GOETEBORGS UNIVERSITET
Sweden
EU contribution
€ 186 880
Address
Vasaparken
405 30 Goeteborg
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Michael Ashton (Prof.)
WORLD HEALTH ORGANIZATION
Switzerland
EU contribution
€ 46 080
Address
Avenue Appia 20
1211 Geneve
Activity type
Research Organisations
Administrative Contact
Piero Olliaro (Prof.)